AstraZeneca launches three-year cost-cutting program to save $1.5 billion annually
AstraZeneca announced a new initiative to reduce costs by $1.5 billion per year over the next three years.
Company targets annual savings
The pharmaceutical company plans to implement these reductions across its operations globally. AstraZeneca states that the money saved will be directed toward research and development projects. The initiative is expected to finish by the end of 2029.
One-time charge details
The firm estimates the program will carry a one-time charge of around $2 billion. There are currently no official comments regarding potential job implications from this initiative. The company faces additional pressure from patent expirations on products like Farxiga.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.